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Chapter 10
A SURVEY OF THE OUTCOME 
OF PROPHYLAXIS,  ON-DEMAND OR 
COMBINED TREATMENT IN 20-35 YEAR OLD 
MEN WITH SEVERE HAEMOPHILIA IN FOUR 
EUROPEAN COUNTRIES 
Declan Noone, Brian O’Mahony, Lucia Prihodova
haemophilia 2011; 17, e842-e843. doI: 10.1111/j.1365-2516.2011.02582.x 
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For children with severe haemophilia, prophylaxis is recognized as the optimum standard of care.1, 2 
It is also one of the principles of haemophilia care espoused by the European Association for Hae-
mophilia and Allied Disorders (EAHAD).3 However, the continuation of prophylactic therapy into 
adulthood is being more closely scrutinized on the grounds of benefit and cost. This study was car-
ried out to examine the long-term effects of prophylaxis and the continuing benefit of the therapy 
in adulthood. National Haemophilia patient organisations in Ireland, UK, France and Sweden were 
asked to participate by randomly selecting 20 severe haemophilia patients between 20 and 35 
years from their database. Of the total of 80 questionnaires, 58 (72.5%) responses were received 
either by mail or by phone interview. Ireland provided 19, UK provided nine, France provided 10 
and Sweden provided 20 responses. The four countries were chosen based on their access to treat-
ment for patients with severe haemophilia. Swedish patients with severe haemophilia have been 
treated with prophylaxis since the late 1970s. Ireland, France and the UK introduced prophylaxis 
in the mid-1990s. The study examined the differences in medical outcomes and quality-of life in 
patients who had full access to primary prophylaxis, entirely on-demand or combinations of thera-
pies. Information on age, country and employment status and responses to an EQ5D questionnaire 
were collected. Medical data was also collected on type and severity of haemophilia, treatment 
regime (prophylaxis vs. on-demand), bleeds per year, target joints, major bleeds (e.g. ilio-psoas 
or intracranial) and days missed from work/college per year. The primary analysis evaluated the 
differences between the four countries, and the secondary analysis examined the differences as 
a proportion of life spent on prophylaxis in comparison to on-demand therapy. The mean age was 
27.5 ± 4.7 years. In the primary analysis of the individual countries, patients in Sweden have spent 
a significantly higher percentage of their life on prophylaxis (p≤0.05), showed the lowest number 
of bleeds/year, lowest presence of target joints (p≤0.001) and major bleeds (p≤0.005), lowest 
number of days missed from work/college, higher scores in Mobility (EQ5D) (p≤0.05) and highest 
utility value. The secondary analysis (Table 10.1) confirmed these findings. Patients always treated 
with prophylaxis reported significantly lower number of bleeds/year than patients treated entirely 
or primarily on-demand (p≤0.05), significantly lower presence of target joints (p≤0.001) and higher 
score in mobility (p≤0.005). Of the respondents who had received prophylaxis all of their lives, five 
reported major bleeds at some point, and five reported target joints without specifying that most 
bleeds occur in these joints. Three of each of these reported both target joints and major bleeds. 
No information on lifestyle or compliance was collected. Patients treated on-demand reported sig-
nificantly higher number of days missed from work than all other groups (p≤0.05) and significantly 
lower score in EQ5D dimension Self-care (p≤0.05). The reported average number of bleeds/year 
for Sweden and France of 3.2 and 20.1, respectively, are broadly consistent with previous studies.4, 5 
The results in the primary analysis for France, UK and Ireland and in the secondary analysis for 
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the on-demand group are also similar to other published work.6, 7 Hence, the results in this study 
support the view that prophylaxis started at a young age and continued into adulthood is an ex-
tremely effective treatment for patients with severe haemophilia. Four patients who were treated 
using prophylaxis switched to on-demand therapy and subsequently reverted to prophylaxis. Nine 
patients (22%), who had been treated primarily with on-demand therapy, have now changed to 
prophylaxis treatment. Respondents in both of these groups reported that this change took place 
due to increased bleeding episodes and/or joint problems that were developing when treated with 
on-demand therapy. When asked about days missed from work, there was a significant difference 
between countries. Swedish respondents reported a mean 0.5 days missed/year from work or 
college for reasons related to haemophilia. In Ireland and the UK, the days missed were 5 and 
6.6 days respectively. With the French respondents, the mean time missed from work or college 
for reasons related to haemophilia was 15 days. This number was dramatically increased by two 
patients in the group not being able to attend work or college for 6 months following orthopaedic 
operations. For adults who have been treated with on-demand therapy, a requirement for orthopae-
dic surgery or joint replacement is not uncommon. This is further supported when the treatment 
regime was examined. Patients on prophylaxis missed a mean of 0.7 days per year and patients 
on-demand missed 19.2 days. The results from the EQ5D demonstrate the clear benefits of long-
term prophylaxis over on-demand therapy. A number of studies on cost effectiveness 8–10 have 
reported the difference in utility values between prophylaxis and on-demand of 0.03 and 0.09. 
This study has shown that the benefit of prophylaxis continued into adulthood increases the util-
ity value by a more significant 0.16–0.20. Overall, on-demand treatment results in a lower utility 
value in relation to quality-of-life for people with severe haemophilia. Prophylaxis started at an 
early age and continued into adulthood results in less bleeding, less damage to joints and less 
time missed at work. Prophylaxis increases mobility and the ability to do everyday activities and 
improves the health-related quality of life of people with severe haemophilia. It would be beneficial 
to extend this survey in the future to gather data on a larger number of people with Haemophilia 
from a larger number of countries and the authors plan to do this. It would be interesting to extend 
this survey to countries where distinctly different prophylaxis regimes are used and to countries 
that use low levels of FVIII per capita to assess what may well be, in effect, a baseline utility figure. 
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Table 10 .1  Results by treatment regime
Reported Mean 


























26.5 88.9 48.5 19.2 0.72
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